# Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp

Source: https://onco.cc/trials/nct07527520/  
OnCo record `nct07527520` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial is a phase 2, randomised interventional study registered as NCT07527520 by Fudan University, with a registry enrolment figure of 165 participants, started 2026-06 and due to reach its primary completion in 2028-07. Interventions recorded: Moderately Hypofractionated Radiotherapy; Serplulimab; CapOx+Long-course radiotherapy. Conditions listed: Rectal Cancer; Moderately Hypofractionated Radiotherapy; Serplulimab; pMMR/MSS. Primary outcome: Complete Remission (CR) Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma with the lower margin of the lesion ≤ 10 cm from the anal verge as assessed by MRI, and immunohistochemistry confirming pMMR, or genetic testing demonstrating MSI-L or MSS". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07527520
- Phase: 2
- Setting: Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial
- Sponsor: Fudan University
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT07527520: https://clinicaltrials.gov/study/NCT07527520

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07527520.json